L
Luis G. Hidalgo
Researcher at University of Alberta
Publications - 58
Citations - 5544
Luis G. Hidalgo is an academic researcher from University of Alberta. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 35, co-authored 53 publications receiving 4565 citations. Previous affiliations of Luis G. Hidalgo include Alberta Health Services.
Papers
More filters
Journal ArticleDOI
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
Joana Sellarés,D. G. de Freitas,Michael Mengel,Jeff Reeve,Gunilla Einecke,Banu Sis,Luis G. Hidalgo,Konrad S. Famulski,Arthur J. Matas,Philip F. Halloran +9 more
TL;DR: This prospective cohort indicates that many actual failures after indication biopsies manifest phenotypic features of antibody‐mediated or mixed rejection and also underscores the major role of nonadherence.
Journal ArticleDOI
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.
Gunilla Einecke,Banu Sis,Jeff Reeve,Michael Mengel,Patricia Campbell,Luis G. Hidalgo,Bruce Kaplan,Philip F. Halloran +7 more
TL;DR: The major cause of late kidney transplant failure is antibody‐mediated microcirculation injury, but detection of this phenotype requires new diagnostic criteria.
Journal ArticleDOI
Molecular diagnosis of antibody-mediated rejection in human kidney transplants.
Joana Sellarés,Jeff Reeve,Alexandre Loupy,Michael Mengel,Banu Sis,Alison Skene,D. G. de Freitas,Chatchai Kreepala,Luis G. Hidalgo,Konrad S. Famulski,Philip F. Halloran +10 more
TL;DR: It is concluded that microarray assessment of gene expression can assign a probability of ABMR to transplant biopsies without knowledge of HLA antibody status, histology, or C4d staining, and predicts future failure.
Journal ArticleDOI
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Farsad Eskandary,Heinz Regele,Lukas Baumann,Gregor Bond,Nicolas Kozakowski,Markus Wahrmann,Luis G. Hidalgo,Helmuth Haslacher,Christopher C. Kaltenecker,Marie-Bernadette Aretin,Rainer Oberbauer,Martin Posch,Anton Staudenherz,Ammon Handisurya,Jeff Reeve,Philip F. Halloran,Georg A. Böhmig +16 more
TL;DR: This trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity, and reinforces the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.
Journal ArticleDOI
A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants
Banu Sis,Gian S. Jhangri,J. Riopel,J. Chang,D. G. de Freitas,Luis G. Hidalgo,Michael Mengel,Arthur J. Matas,Philip F. Halloran +8 more
TL;DR: Any degree of microcirculation inflammation in late kidney transplant biopsies strongly indicates presence of DSA and predicts progression to graft failure and a decision tree was built and validated to predict DSA.